Health ❯ Healthcare ❯ Patient Care

Treatment Options

Oral Medications Innovative Therapies Combination Therapy Subcutaneous Administration Cognitive Impairment Chemotherapy Cancer Treatment Personalized Medicine Immunotherapy Therapies

FDA Clears Once-Weekly Saphnelo Pen for Self-Injection in Lupus

Phase 3 data showed lower disease activity with safety matching the IV form.

KRAS Pill Doubles Survival in Trial as Pancreatic Cancer Vaccine Advances

Revolution Medicines’ Pancreatic Cancer Drug Lands ASCO Plenary After Phase 3 Survival Gain

First-in-Human SynKIR-110 Shows Safe Profile and Early Activity in Solid Tumors

Revolution Medicines Drug Nearly Doubles Survival in Phase 3 Pancreatic Cancer Trial

FDA Approves Filspari to Reduce Proteinuria in FSGS Patients Without Nephrotic Syndrome

NIH-Funded Trial Finds Vein Stents Ease Post-Thrombotic Syndrome

AstraZeneca’s Imfinzi–Imjudo Regimen Improves Progression-Free Survival in Liver Cancer Trial

Mavacamten Cuts Heart Outflow Obstruction in Teens in First Randomized Trial

FDA Approves Higher‑Dose Spinraza Regimen for Spinal Muscular Atrophy

FDA Approves First Glucocorticoid Receptor Blocker for Platinum-Resistant Ovarian Cancer

Apogee to Report 52-Week Phase 2 Data for Zumilokibart in Atopic Dermatitis Today

FDA Clears J&J’s Icotyde, First Oral IL-23 Psoriasis Therapy for Ages 12 and Up

Trump Says Chief of Staff Susie Wiles Has Early-Stage Breast Cancer

Repurposed Epilepsy Drug Cuts Sleep Apnea Events by Up to 47% in Phase II Trial

São Paulo Council Honors Polylaminin Scientist as Anvisa Approves Compassionate Use for 33 Patients

Polilaminina Enters Regulated Testing as Lead Researcher Moves to Correct Preprint

Early Trial of VIR-5500 Shrinks Tumors in 45% of Advanced Prostate Cancer Cases

CHMP Backs Xolremdi for WHIM Syndrome Under Exceptional Circumstances

Lilly’s Oral GLP-1 Orforglipron Tops Oral Semaglutide in Lancet Phase 3 Diabetes Trial